Program
linvoseltamab
Also written as “Linvoseltamab” and “REGN7945+Linvoseltamab”.
Its studies are mostly in Multiple Myeloma · Immunoglobulin Light-chain Amyloidosis · Monoclonal Gammopathy of Undetermined Significance · Food Hypersensitivity · Smoldering Multiple Myeloma, led by Regeneron Pharmaceuticals.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 1312 open or running | phase 4since May 20, 2026 | Nov 29, 2018 | Aug 31, 2027phase 1 · NCT06369467 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 29, 2018First study: phase 2 study in Multiple MyelomaFirst studyNCT03761108 · 387 planned · United States, Belgium, Germany and more
- Feb 6, 2023Phase 3 study in Multiple MyelomaNCT05730036 · 410 planned · United States, Australia, Belgium and more
- Apr 12, 2023Phase 2 study in Multiple MyelomaNCT05828511 · 148 enrolled · United States, France, Spain
- Jul 13, 2023Phase 2 study in Smoldering Multiple MyelomaNCT05955508 · 40 enrolled · Spain
- Oct 31, 2023Phase 2 study in Monoclonal Gammopathy of Undetermined SignificanceNCT06140524 · 116 planned · United States, Belgium, France and more
- Feb 27, 2024Phase 2 study in RecurrenceNCT06292780 · 220 planned · United States, Greece, South Korea and more
- Apr 11, 2024Phase 1 study in Food HypersensitivityNCT06369467 · 6 enrolled · United States
- Oct 30, 2024Phase 2 study in Multiple MyelomaNCT06669247 · 186 planned · Australia, United Kingdom
- Oct 28, 2025Phase 3 study in Relapsed and/or Refractory Multiple Myeloma (RRMM)NCT07222761 · 915 planned · United States, Australia, Brazil and more
- Jan 29, 2026Phase 3 study in Multiple MyelomaNCT07393282 · 270 planned · United States, France, Japan and more
- Feb 3, 2026Phase 3 study in Multiple MyelomaNCT07428369
- May 20, 2026Phase 4 study in Multiple MyelomaNCT07609940 · 30 planned · United States
- Oct 22, 2026Phase 3 study in Immunoglobulin Light-chain AmyloidosisNCT07901725 · 382 planned
Ahead
- Aug 31, 2027Primary completion: phase 1 study in Food HypersensitivityNCT06369467
- Oct 11, 2027Primary completion: phase 4 study in Multiple MyelomaNCT07609940
- Aug 20, 2028Primary completion: phase 2 study in RecurrenceNCT06292780
- May 21, 2029Primary completion: phase 3 study in Relapsed and/or Refractory Multiple Myeloma (RRMM)NCT07222761
TargetBeta
“A human, immunoglobulin G4 (IgG4) bispecific antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and the T-cell surface antigen CD3, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elranatamabrule | Pfizer | phase 4 | 15 |
| teclistamabrule | Johnson & Johnson | phase 4 | 11 |
| etentamig | AbbVie | phase 3 | 11 |
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| cizutamigrule | UCB | phase 2 | 5 |
| vonsetamigrule | Regeneron Pharmaceuticals | phase 2 | 3 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010rule | kelonia-therapeutics-inc | phase 1 | 1 |
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07901725Immunoglobulin Light-chain Amyloidosis | 3 | Not yet recruiting | Jul 25, 2035 | 382 |
| NCT07609940Multiple Myeloma · United States | 4 | Recruiting | Oct 11, 2027 | 30 |
| NCT07428369Multiple Myeloma | 3 | Withdrawn | May 21, 2038 | 0 |
| NCT07393282Multiple Myeloma · United States, France, Japan and more | 3 | Recruiting | Jul 27, 2033 | 270 |
| NCT07222761Relapsed and/or Refractory Multiple Myeloma (RRMM) · United States, Australia, Brazil and more | 3 | Recruiting | May 21, 2029 | 915 |
| NCT06669247Multiple Myeloma · Australia, United Kingdom | 2 | Recruiting | Nov 11, 2033 | 186 |
| NCT06369467Food Hypersensitivity · United States | 1 | Active, not recruiting | Aug 31, 2027 | 6 |
| NCT06292780Recurrence · United States, Greece, South Korea and more | 2 | Recruiting | Aug 20, 2028 | 220 |
| NCT06140524Monoclonal Gammopathy of Undetermined Significance · United States, Belgium, France and more | 2 | Recruiting | May 18, 2032 | 116 |
| NCT05955508Smoldering Multiple Myeloma · Spain | 2 | Active, not recruiting | Jan 25, 2033 | 40 |
| NCT05828511Multiple Myeloma · United States, France, Spain | 2 | Active, not recruiting | Nov 2, 2035 | 148 |
| NCT05730036Multiple Myeloma · United States, Australia, Belgium and more | 3 | Recruiting | Apr 19, 2033 | 410 |
| NCT03761108Multiple Myeloma · United States, Belgium, Germany and more | 2 | Recruiting | Mar 30, 2033 | 387 |
How it is read
Names in the registry
- “Linvoseltamab”, 12 entries
- “REGN7945+Linvoseltamab”, 1 entry
- “linvoseltamab”, 1 entry
Conditions, from the studies’ own filings
- Multiple Myeloma, 8 studies
- Immunoglobulin Light-chain Amyloidosis, 1 study
- Monoclonal Gammopathy of Undetermined Significance, 1 study
- Food Hypersensitivity, 1 study
- Smoldering Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.